Pathogenesis of Sjögren's syndrome

Current Opinion in Rheumatology

Volumn 21, Issue 5, 2009, Pages 465-470

  Nikolov, Nikolay P ^a   Illei, Gabor G ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Autonomic nervous system; Exocrinopathy; Innate immunity; Sex steroids

Indexed keywords

ALPHA INTERFERON; AQUAPORIN 5; B CELL ACTIVATING FACTOR; B LYMPHOCYTE RECEPTOR; CASPASE 11; CHEMOKINE RECEPTOR CCR5; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 23; INTERLEUKIN 4; MUSCARINIC RECEPTOR; PRASTERONE; PRASTERONE SULFATE; STAT1 PROTEIN; STAT6 PROTEIN; TOLL LIKE RECEPTOR 3;

ANDROGEN DEFICIENCY; AUTONOMIC NEUROPATHY; ENVIRONMENTAL FACTOR; HUMAN; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; REVIEW; SALIVARY GLAND; SALIVARY GLAND DISEASE; SJOEGREN SYNDROME; T LYMPHOCYTE ACTIVATION; TH17 CELL;

ANIMALS; AUTOANTIBODIES; AUTONOMIC NERVOUS SYSTEM; B-CELL ACTIVATING FACTOR; CAUSALITY; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; RECEPTORS, MUSCARINIC; SEX CHARACTERISTICS; SJOGREN'S SYNDROME;

EID: 69549135995     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32832eba21     Document Type: Review

References (39)

1. Deshmukh US, Ohyama Y, Bagavant H, et al. Inflammatory stimuli accelerate Sjögren's syndrome-like disease in (NZBxNZW)F1 mice. Arthritis Rheum 2008;58:1318-1323. The article studies the role of nonspecific inflammation in accelerating the glandular dysfunction early in life prior to development of systemic autoimmunity. (Pubitemid 351705921)
2. Deshmukh US, Nandula SR, Thimmalapura PR, et al. Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function. J Oral Pathol Med 2009;38:42-47.
3. Bulosan M, Pauley KM, Yo K, et al. Inflammatory caspases are critical for enhanced cell death in the target tissue of Sjögren's syndrome before disease onset. Immunol Cell Biol 2009;87:81-90.
4. Nguyen CQ, Hu MH, Li Y, et al. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjögren's syndrome: findings in humans and mice. Arthritis Rheum 2008;58:734-743. The study implicates that IL-4/STAT6 signaling pathway defects as the molecular mechanisms required for the evolution form target organ inflammation to dysfunction.
5. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, et al. Systemic increase in type I interferon activity in Sjögren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol 2008;38:2024-2033.
6. Ishimaru N, Arakaki R, Yoshida S, et al. Expression of the retinoblastoma protein RbAp48 in exocrine glands leads to Sjögren's syndrome-like autoimmune exocrinopathy. J Exp Med 2008;205:2915-2927. A very interesting study that implicates salivary gland epithelial cells as anti-genpresenting cells driving adaptive immune responses supporting the role of mucosal immunity in the pathogenesis of Sjögren's syndrome.
7. Nguyen CQ, Kim H, Cornelius JG, et al. Development of Sjögren's syndrome in nonobese diabetic-derived autoimmune-prone C57BL/6.NOD-Aec1Aec2 mice is dependent on complement component-3. J Immunol 2007; 179:2318-2329.
8. NandulaSR, Amarnath S,Molinolo A, et al.Female mice are more susceptible to developing inflammatory disorders due to impaired transforming growth factor beta signaling in salivary glands. Arthritis Rheum 2007;56:1798-1805.
9. Soyfoo MS, De Vriese C, Debaix H, et al. Modified aquaporin 5 expression and distribution in submandibular glands from NOD mice displaying autoimmune exocrinopathy. Arthritis Rheum 2007;56:2566-2574. (Pubitemid 47237275)
10. Ohashi Y, Tsuzaka K, Takeuchi T, et al. Altered distribution of aquaporin 5 and its C-terminal binding protein in the lacrimal glands of a mouse model for Sjögren's syndrome. Curr Eye Res 2008;33:621-629.
11. Li X, Azlina A, Karabasil MR, et al. Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor agonist. Am J Physiol Gastrointest Liver Physiol 2008;295:G112-G123. This is a very interesting study implicating AQP5 degradation as a nonimmune mechanism in the pathogenesis of glandular dysfunction.
12. Berggreen E, Nylokken K, Delaleu N, et al. Impaired vascular responses to parasympathetic nerve stimulation and muscarinic receptor activation in the submandibular gland in nonobese diabetic mice. Arthritis Res Ther 2009;11:R18.
13. Valtysdottir ST, Wide L, Hallgren R. Low serum dehydroepiandrosterone sulfate in women with primary Sjögren's syndrome as an isolated sign of impaired HPA axis function. J Rheumatol 2001;28:1259-1265. (Pubitemid 32510496)
14. Laine M, Porola P, Udby L, et al. Low salivary dehydroepiandrosterone and androgen-regulated cysteine-rich secretory protein 3 levels in Sjögren's syndrome. Arthritis Rheum 2007;56:2575-2584. (Pubitemid 47237276)
15. Porola P, Virkki L, Przybyla BD, et al. Androgen deficiency and defective intracrine processing of dehydroepiandrosterone in salivary glands in Sjögren's syndrome. J Rheumatol 2008;35:2229-2235. This study describes the defect in the intracrine processing of DHEA in the salivary gland of Sjögren's patients.
16. Spaan M, Porola P, Laine M, et al. Healthy human salivary glands contain a DHEA-S processing intracrine machinery, which is deranged in primary Sjögren's syndrome. J Cell Mol Med 2009. [Epub ahead of print]
17. Forsblad d'Elia H, Carlsten H, Labrie F, et al. Low serum levels of sex-steroids are associated with disease characteristics in primary Sjögren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. J Clin Endocrinol Metab 2009;94:2044-2051.
18. Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci U S A 2006;103:2770-2775. (Pubitemid 43306624)
19. Hjelmervik TO, Petersen K, Jonassen I, et al. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects. Arthritis Rheum 2005;52:1534-1544. (Pubitemid 40663945)
20. Emamian ES, Leon JM, Lessard CJ, et al. Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun 2009;10:285-296. First study evaluating gene expression profiles in whole blood and PBMCs of Sjögren's patients. Data are confirmed in an independent cohort.
21. Moutsopoulos NM, Katsifis GE, Angelov N, et al. Lack of efficacy of etanercept in Sjogren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis 2008;67:1437-1443.
22. Niewold TB, Rivera TL, Buyon JP, et al. Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. Arthritis Rheum 2008;58:541-546.
23. Mavragani CP, Niewold TB, Moutsopoulos NM, et al. Augmented interferonalpha pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis Rheum 2007;56:3995-4004.
24. Ittah M,Miceli-Richard C, Gottenberg JE, et al. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways. Eur J Immunol 2008;38:1058-1064. Both poly (I:C), a synthetic TLR3 agonist and a double-stranded RNA (dsRNA), virus induced high expression of BAFF in salivary gland epithelial cells. Inhibition of the endosome or IFN only partially blocked this effect.
25. Lavie F, Miceli-Richard C, Ittah M, et al. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome. Scand J Immunol 2008; 67:185-192.
26. Sellam J, Miceli-Richard C, Gottenberg JE, et al. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus. Ann Rheum Dis 2007;66:790-797. (Pubitemid 46846699)
27. Daridon C, Devauchelle V, Hutin P, et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 2007;56:1134-1144. (Pubitemid 46608638)
28. Andonopoulos AP, Christodoulou J, Ballas C, et al. Autonomic cardiovascular neuropathy in Sjögren's syndrome: a controlled study. J Rheumatol 1998; 25:2385-2388. (Pubitemid 28551856)
29. Cai FZ, Lester S, Lu T, et al. Mild autonomic dysfunction in primary Sjögren's syndrome: a controlled study. Arthritis Res Ther 2008;10:R31. The study confirmed the presence of sympathetic and parasympathetic autonomic abnormalities in patients with Sjögren's syndrome.
30. Kovacs L, Papos M, Takacs R, et al. Autonomic nervous system dysfunction involving the gastrointestinal and the urinary tracts in primary Sjögren's syndrome. Clin Exp Rheumatol 2003;21:697-703. (Pubitemid 38008751)
31. Mandl T, Granberg V, Apelqvist J, et al. Autonomic nervous symptoms in primary Sjögren's syndrome. Rheumatology (Oxford) 2008;47:914-919. (Pubitemid 351796384)
32. Barendregt PJ, Visser MR, Smets EM, et al. Fatigue in primary Sjögren's syndrome. Ann Rheum Dis 1998;57:291-295.
33. Mandl T, Ekberg O, Wollmer P, et al. Dysphagia and dysmotility of the pharynx and oesophagus in patients with primary Sjögren's syndrome. Scand J Rheumatol 2007;36:394-401. (Pubitemid 350034805)
34. Dawson L, Tobin A, Smith P, et al. Antimuscarinic antibodies in Sjögren's syndrome: where are we, and where are we going? Arthritis Rheum 2005; 52:2984-2995.
35. Koo NY, Li J, Hwang SM, et al. Functional epitope of muscarinic type 3 receptor which interacts with autoantibodies from Sjögren's syndrome patients. Rheumatology (Oxford) 2008;47:828-833. (Pubitemid 351796368)
36. Schegg V, Vogel M, Didichenko S, et al. Evidence that antimuscarinic antibodies in Sjögren's syndrome recognise both M3R and M1R. Biologicals 2008;36:213-222.
37. Kovacs L, Feher E, Bodnar I, et al. Demonstration of autoantibody binding to muscarinic acetylcholine receptors in the salivary gland in primary Sjögren's syndrome. Clin Immunol 2008;128:269-276.
38. Tracey KJ. Physiology and immunology of the cholinergic anti-inflammatory pathway. J Clin Invest 2007;117:289-296. (Pubitemid 46203953)
39. van Maanen MA, Vervoordeldonk MJ, Tak PP. The cholinergic anti-inflammatory pathway: towards innovative treatment of rheumatoid arthritis. Nat Rev Rheumatol 2009;5:229-232.